On March 15th, Baekje announced that the US Food and Drug Administration (FDA) has approved tirizizumab (Chinese trade name: Baekzean®; English trade name: TEVIMBRA®) as a monotherapy for adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have previously received systemic chemotherapy (excluding PD-1/L1 inhibitors). Tirelizumab is expected to be launched in the United States in the second half of 2024. This approval marks the first indication for tirizumab in the United States.